RU94036772A - Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза - Google Patents

Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза

Info

Publication number
RU94036772A
RU94036772A RU94036772/14A RU94036772A RU94036772A RU 94036772 A RU94036772 A RU 94036772A RU 94036772/14 A RU94036772/14 A RU 94036772/14A RU 94036772 A RU94036772 A RU 94036772A RU 94036772 A RU94036772 A RU 94036772A
Authority
RU
Russia
Prior art keywords
endometriosis
phenyl
aroylbenzothiophenes
inhibition
application
Prior art date
Application number
RU94036772/14A
Other languages
English (en)
Other versions
RU2157203C2 (ru
Inventor
Джон Блэк Ларри
Us]
Джозеф Каллинан Джордж
Уильям Дрейпер Майкл
Дэвид Джоунз Чарлз
Эдвард Сейлер Дэвид
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94036772A publication Critical patent/RU94036772A/ru
Application granted granted Critical
Publication of RU2157203C2 publication Critical patent/RU2157203C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cable Transmission Systems, Equalization Of Radio And Reduction Of Echo (AREA)

Abstract

Способ ингибирования эндометриоза, заключающийся в назначении человеку, нуждающемуся в лечении или профилактике эффективного количества соединения, имеющего формулу, приведенную в описании, или фармацевтически приемлемой соли или сольвата его.

Claims (1)

  1. Способ ингибирования эндометриоза, заключающийся в назначении человеку, нуждающемуся в лечении или профилактике эффективного количества соединения, имеющего формулу, приведенную в описании, или фармацевтически приемлемой соли или сольвата его.
RU94036772/14A 1993-10-15 1994-10-13 Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза RU2157203C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/138,643 1993-10-15
US08/138,643 US5461065A (en) 1993-10-15 1993-10-15 Methods for inhibiting endometriosis

Publications (2)

Publication Number Publication Date
RU94036772A true RU94036772A (ru) 1996-08-27
RU2157203C2 RU2157203C2 (ru) 2000-10-10

Family

ID=22482966

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94036772/14A RU2157203C2 (ru) 1993-10-15 1994-10-13 Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза

Country Status (25)

Country Link
US (2) US5461065A (ru)
EP (1) EP0652005B1 (ru)
JP (1) JPH07188014A (ru)
KR (1) KR950010893A (ru)
CN (1) CN1049335C (ru)
AT (1) ATE203404T1 (ru)
AU (1) AU677700B2 (ru)
CA (1) CA2118092A1 (ru)
CZ (1) CZ287246B6 (ru)
DE (1) DE69427800T2 (ru)
DK (1) DK0652005T3 (ru)
ES (1) ES2157957T3 (ru)
GR (1) GR3036971T3 (ru)
HU (1) HUT71235A (ru)
IL (1) IL111284A (ru)
NO (1) NO311242B1 (ru)
NZ (1) NZ264677A (ru)
PH (1) PH31261A (ru)
PT (1) PT652005E (ru)
RU (1) RU2157203C2 (ru)
SG (1) SG43319A1 (ru)
SI (1) SI0652005T1 (ru)
TW (1) TW296382B (ru)
UA (1) UA26930C2 (ru)
ZA (1) ZA948029B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
ES2155895T3 (es) * 1994-08-22 2001-06-01 Lilly Co Eli Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para inhibir la hiperplasia endometrial primaria.
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses
US5554600A (en) * 1995-01-20 1996-09-10 Eli Lilly And Company Methods for inhibiting endometriosis
ES2124064T3 (es) * 1995-06-07 1999-01-16 Lilly Co Eli Compuestos y composiciones con cadenas laterales nitrogenadas no basicas.
KR970002795A (ko) 1995-10-30 1997-01-28 모리 하루오 네비게이션(navigation)장치
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5942539A (en) * 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000030684A1 (fr) * 1998-11-26 2000-06-02 Teikoku Hormone Mfg. Co., Ltd. Compositions medicamenteuses a administration periodique
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
WO2002056903A2 (en) * 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
ATE321754T1 (de) * 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
DE60202954T2 (de) * 2001-05-22 2006-01-05 Eli Lilly And Co., Indianapolis Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
SE500453C2 (sv) * 1991-10-07 1994-06-27 Karobio Ab Ett in vitro förfarande för utvärdering av en substans effekter
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
DE69427800D1 (de) 2001-08-30
CN1049335C (zh) 2000-02-16
PH31261A (en) 1998-06-18
CA2118092A1 (en) 1995-04-16
TW296382B (ru) 1997-01-21
CZ253794A3 (en) 1995-05-17
KR950010893A (ko) 1995-05-15
HU9402959D0 (en) 1995-02-28
EP0652005B1 (en) 2001-07-25
IL111284A0 (en) 1994-12-29
AU7578794A (en) 1995-05-04
IL111284A (en) 2000-02-29
NO311242B1 (no) 2001-11-05
CN1107043A (zh) 1995-08-23
DK0652005T3 (da) 2001-09-24
NO943879L (no) 1995-04-18
RU2157203C2 (ru) 2000-10-10
US5461065A (en) 1995-10-24
JPH07188014A (ja) 1995-07-25
ZA948029B (en) 1996-04-15
CZ287246B6 (en) 2000-10-11
AU677700B2 (en) 1997-05-01
HUT71235A (en) 1995-11-28
UA26930C2 (uk) 1999-12-29
EP0652005A1 (en) 1995-05-10
ES2157957T3 (es) 2001-09-01
US5693656A (en) 1997-12-02
GR3036971T3 (en) 2002-01-31
ATE203404T1 (de) 2001-08-15
NZ264677A (en) 1997-07-27
PT652005E (pt) 2001-11-30
DE69427800T2 (de) 2001-12-06
SI0652005T1 (en) 2001-12-31
NO943879D0 (no) 1994-10-13
SG43319A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
RU94044488A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования симптомов пременструального синдрома/ дисфории, связанной с поздней лютеальной фазой
RU94044454A (ru) Ингибитор аутоимунных заболеваний
GB0225475D0 (en) Therapeutic agents
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
RU94037235A (ru) Ингибитор фиброза матки
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
DE69413237T2 (de) Plättchenaggregationsinhibitoren
RU94036771A (ru) Ингибиторы ангиогенеза и ангиогенных заболеваний
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
RU94044321A (ru) Средство повышения либидо у женщин постклимактерического периода
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
RU94045277A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования расстройств цнс у женщин в постменопаузе
RU94045156A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания
DE69315699D1 (de) Inhibitoren gegen die aggregation von blutplättchen
RU94045272A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения овариального дисгенеза, задержки полового созревания или сексуального инфантелизма